Endogenous cysteinyl leukotriene synthesis was assessed in 10 patients with Kawasaki disease and 10 healthy controls by measuring excretion of leukotriene E4 (LTE4) in urine. LTE4 was increased more than fivefold in patients with Kawasaki disease compared with controls (median (range) 55.3 (31-8-120-6) v 10-2 (7.1-14.9) nmollmol creatinine); this suggests that cysteinyl leukotrienes are involved in the pathophysiology of Kawasaki disease. Leukotriene synthetase inhibition or receptor antagonism may therefore offer a new potential therapeutic approach in children with this disease. (Arch Dis Child 1995; 72: 526-527 
In healthy children and patients with Kawasaki disease the excretion of LTE4 was log normally distributed. The patients with Kawasaki disease excreted more than fivefold higher amounts of LTE4 into urine than did the age and sex matched healthy controls (p<0-01). The median (range) was 55X3 (31-8-120-6) nmol/mol creatinine for the patients and 10-2 (7-1-14-9) nmol/mol creatinine for the controls (figure). 4 However, in vitro data from isolated cells must be interpreted cautiously, as characteristically cells must be incubated with labelled arachidonic acid or appropriately stimulated to synthesise eicosanoids such as thromboxane or leukotrienes.
Urinary LTE4 excretion, however, is a reliable index metabolite to assess whole body synthesis of cysteinyl leukotrienes in vivo. 5 The present findings therefore strongly suggest that cysteinyl leukotriene synthesis and generation is enhanced in Kawasaki disease.
It must be pointed out, however, that urinary LTE4 is not a specific marker for Kawasaki disease. In other diseases, such as asthma, cystic fibrosis, and juvenile rheumatoid arthritis, an enhanced urinary excretion of LTE4 has been demonstrated.5 This implies that LTE4 is not specific for a single disease but might provide a sensitive index of inflammation. In Kawasaki disease increased synthesis of cysteinyl leukotrienes might mediate certain symptoms associated with the disease. For example, it has been pointed out that cysteinyl leukotrienes are released during episodes of myocardial ischaemia providing evidence for their involvement during and after acute myocardial infarction and unstable angina attacks.6 Therefore and because of their potent vasoconstrictive capacity, cysteinyl leukotrienes might be involved in the origin of vasculitis and stenosis of coronary arteries in Kawasaki disease.
The definitive role of cysteinyl leukotrienes in Kawasaki disease has to be evaluated in further studies by the use of specific 5-lipoxygenase inhibitors or receptor antagonists. Measurement of urinary LTE4 provides a noninvasive and specific method useful to monitor the effect of these drugs on leukotriene synthesis in Kawasaki disease. Our results imply that leukotriene synthetase inhibition or receptor antagonism may offer a new potential therapeutic approach in children with Kawasaki disease. 
